North America Legal Cannabis Market Size, Share, Trends and Forecast Report 2025-2033
North American Legal Cannabis Market
Dublin, July 10, 2025 (GLOBE NEWSWIRE) -- The "North America Legal Cannabis Market Size, Share, Trends and Forecast by Products Derived, Distribution Channel, and Country, 2025-2033" has been added to ResearchAndMarkets.com's offering.
The North America legal cannabis market was valued at USD 44.83 Billion in 2024 and is projected to reach USD 354.82 Billion by 2033, with a compound annual growth rate of 24.55% from 2025-2033. This exponential market expansion is propelled by increasing legalization, rising medical applications, and growing consumer demand for diverse products. Advancements in regulation, investments, and technological innovations in cultivation and extraction processes are pivotal growth drivers.
The U.S. and Canada are at the forefront, with state-level legalizations in the U.S. and full federal legalization in Canada fueling the market. The demand for cannabis-based pharmaceuticals is on the rise, driven by clinical research supporting therapeutic benefits for conditions like chronic pain, anxiety, and epilepsy, leading to accelerated medical adoption.
A clinical trial by Johns Hopkins and Tufts University revealed that dronabinol, a synthetic cannabis pill, can reduce agitation in Alzheimer's patients by 30%, offering similar calming effects without severe side effects compared to traditional treatments. This research underscores the transformative potential of cannabis in medical treatments and is shifting public perception, leading to increased investments and product innovation.
The economic advantages such as job creation and tax revenue are compelling more state governments to legalize cannabis. Product diversification is evident as edibles, beverages, and wellness products gain popularity. In September 2024, Tilray Brands unveiled plans to introduce Delta-9 THC drinks, including mocktails and seltzers, to U.S. markets, catering to diverse consumer preferences. Similarly, Seth Rogen's Houseplant launched THC-infused sparkling waters in December 2024, tapping into demand for smoke-free, low-calorie options.
Technological advancements are enhancing consistency and quality in cultivation and extraction. There is a growing consumer preference for organic and sustainably sourced cannabis, prompting companies to adopt eco-friendly practices. Collaborations and investments from mainstream industries like pharmaceuticals and beverages further cement the market's growth.
Key Trends:
Product Diversification: The industry is experiencing significant product diversification, including edibles, cannabis-infused drinks, and topicals to cater to wellness-oriented consumers. Brands are also innovating with functional formulations combining cannabinoids with adaptogens and vitamins for stress relief, sleep, and relaxation.
Rising Medical Applications: Clinical research is expanding the adoption of medical cannabis, with confirmed efficacy in managing chronic pain, epilepsy, and mental health disorders. The growing acceptance among healthcare professionals and patients is boosting demand and facilitating regulatory advancements to ensure product safety.
Retail and E-Commerce Growth: The market is witnessing robust growth in retail and online sales as consumers seek convenience and access. Initiatives like DoorDash's home delivery for cannabis products respond to rising consumer demand, offering items like gummies and beverages in legally permissible states.
Industry Segmentation:
Analysis by product shows that marijuana remains dominant, supported by legalization and consumer demand for high-THC products. Regulated dispensaries lead in distribution channels, favored for adhering to government regulations and providing lab-tested, safe products.
Competitive Landscape: The competitive landscape is characterized by product innovation, strategic partnerships, and geographic expansion. Companies focus on advanced cultivation techniques, extraction technologies, and sustainable production. Efforts to enhance testing, labeling, and consumer education underline the importance of regulatory compliance.
Major Companies:
22nd Century Group, Inc.
Medical Marijuana Inc.
Hemp, Inc.
Axim Biotechnologies, Inc.
Arena Pharmaceuticals, Inc.
Canopy Growth Corporation
Aphria Inc.
Aurora Cannabis Inc.
Abcann Medicinals Inc.
Key Questions Addressed:
How big is the legal cannabis market in North America?
What factors are driving the market growth?
What is the forecast through 2033?
Which segment holds the largest market share?
Who are the leading market players?
Key Attributes:
Report Attribute
Details
No. of Pages
123
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$44.83 Billion
Forecasted Market Value (USD) by 2033
$354.82 Billion
Compound Annual Growth Rate
25.8%
Regions Covered
North America
For more information about this report visit https://www.researchandmarkets.com/r/8bec24
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
North American Legal Cannabis Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
6 minutes ago
- CBS News
Isleton City Council structure shaken up, meeting turns to chaos
There's political drama in the Delta, after the Isleton City Council ousted the mayor as part of a reorganization, naming a new mayor and vice mayor from within the council. Tensions were high at a chaotic meeting on Tuesday, where CBS Sacramento's camera was rolling. As the meeting went on, insults, opinions, and frustrations were shared by councilmembers, city staff, and members of the public who were in attendance in a packed city hall. Expletives were regularly thrown into comments and grievances from all sides. At the center of one of the most contested items was the now-former mayor, Iva Walton. Walton was accused of continuing to operate an outdoor dining area at her bar, Mei Wah Beer Room, after her encroachment permit was denied. At one point, Walton said: "It feels like dumping when her [councilmember Aleida Suarez] wife calls me a 'bad dog.' " Suarez responded: "You call us coffee b-----," adding, "this isn't about he said she said. This is about code of conduct." At times, other members of the public blurted out expletives as councilmembers spoke to each other, at times, outlining negative or untrue social media posts made about each other. Isleton has a $4.7 million debt, and a recent grand jury report outlined systemic issues that put the city on the brink of bankruptcy. Tuesday night, before chaos erupted, the council voted to send a letter of request to the Sacramento County Board of Supervisors requesting an $800,000 loan to address some of their immediate debts. Members of the public expressed concern amid the tense exchanges and council upheaval that the perception of their city may be impacted if they receive the county loan. "We just have to look at the future and how the person that's going to give us a loan and looks at what you guys are doing now. There's a TV camera here, there's a reporter here. How do you want to look to the public?" one speaker said. CBS Sacramento took the concerns about the impacts of the meeting to the city's acting finance director, who said on Wednesday that the city manager spent most of the day doing "damage control." "Change is going to be painful. This city has operated for one way for decades. To put them on the right path, it's going to look really rocky," said Jessica Bigby, acting finance director of Isleton. The now-mayor, David Kent, told CBS Sacramento it was good to get all of the thoughts, feelings, and opinions out in the open. "A bit of a deviation of sort of the standard session you would expect, but it was healthy and necessary in my opinion," said Kent. In a statement to CBS13, Walton said she believed the proper procedure was not followed, "and the complaints were largely personal attacks and had nothing to do with the leadership I brought to the chair/mayor council position."
Yahoo
24 minutes ago
- Yahoo
Kuros Biosciences Reports First Half of 2025 Results
Kuros Biosciences Reports First Half of 2025 Results Financial Highlights Total Medical Device sales rose by 78% to USD 63.5 million in H1 2025 (H1 2024: USD 35.7 million) Direct MagnetOs™ sales increased by 77% to USD 62.7 million in H1 2025 (H1 2024: USD 35.4 million) The Group achieved its first-ever operating profit, reaching USD 3.5 million, compared to an operating loss of USD (0.2) million in H1 2024 Total Group EBITDA reached USD 5.1 million in H1 2025 (H1 2024: USD 0.8 million) and total Group adjusted EBITDA* amounted to USD 7.8 million in H1 2025, equaling a margin of 12.3% (H1 2024: USD 4.5 million at 12.6%). After amortization, depreciation, the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million) Cash position remains strong while funding strategic growth initiatives and investing in working capital, with cash and cash equivalents totaling USD 18.4 million as of June 30, 2025 (December 31, 2024: USD 19.8 million) Reporting currency changed from CHF to USD to align with the Group's primary market and operational footprint in the U.S. The Group continues to expect sales growth of at least 60% in 2025 and anticipates sales of between USD 220 million and USD 250 million by 2027 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences ('Kuros' or the 'Company') a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. Revenue from Direct MagnetOs product sales increased 77% year-on-year to USD 62.7 million (H1 2024: USD 35.4 million). The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an operating loss of USD (0.2) million in H1 2024. The Group achieved an EBITDA of USD 5.1 million in H1 2025, increasing from USD 0.8 million in H1 2024. Adjusted EBITDA* totaled at USD 7.8 million, up from USD 4.5 million in H1 2024. This represents an adjusted EBITDA* margin of 12.3%. The Group does not expect a material impact from U.S. tariffs in 2025. Finally, the reporting currency was changed from Swiss francs (CHF) to U.S. dollars (USD) to reflect the Group's primary market and business activities. Chris Fair, Chief Executive Officer of Kuros Biosciences, said: 'We recorded exceptional company revenue growth of 78%, marking a pivotal phase of scale and impact for Kuros. An outstanding accomplishment is that the group has for the first time ever recorded an operating profit. With FDA clearance and U.S. launch of MagnetOs MIS, accelerating growth in extremities, and entry into new international markets, we continue to deliver with innovation, precision, and purpose. The strategic alliance with Medtronic is expanding our reach across U.S. spine markets, while our new Atlanta headquarters will enable domestic production and an immersive educational experience for surgeons, partners, and investors. Backed by strong financial performance, an experienced and diverse board, and momentum across all segments, we are well-positioned to sustain growth and create long-term value for patients, providers, and shareholders globally.' Commercial, Operational & Regulatory Highlights Medtronic U.S. Spine Partnership Gains Traction – In January 2025, Kuros finalized a five-year exclusive strategic sales agent agreement with the Medtronic spinal division for MagnetOs in mutually agreed upon U.S. sales territories. The partnership, which evolved from a successful pilot, is accelerating commercial access and hospital entry across key geographies, serving as a major force multiplier for Kuros' U.S. growth. FDA Clearance & First Cases with MagnetOs MIS Delivery System – Kuros has received FDA 510(k) clearance for its MagnetOs MIS Delivery System, a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine procedures. The system enables three times faster graft placement compared to traditional funnel-based methods, combining precise delivery with compelling Level I clinical data.1,2 Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. 'MagnetOs MIS delivered smooth, precise graft placement in a typically challenging MIS TLIF case – no preparation, no thawing, just immediate delivery and efficiency. It pairs streamlined handling with compelling clinical data, making it a meaningful advancement for surgeons who value both efficiency and biologically robust healing,' said Dr. Park. Continued Momentum in Extremities Market – With an established team dedicated to the extremities segment, Kuros is laying the groundwork for long-term success. Early progress has been promising, and the team continues to focus on targeted surgeon and distributor engagement, training, and brand awareness through an omnichannel strategy that includes key scientific meetings and driving social media presence. Global Expansion Accelerates – Following recent approval of MagnetOs Granules, ANVISA has now approved MagnetOs Putty for use in Brazil, further expanding Kuros' commercial presence in the growing South American spine market and building on recent global clearances in Lebanon and beyond. First Capital Markets Day Successfully Completed – In May 2025, Kuros hosted its inaugural Capital Markets Day in Zurich, welcoming over 130 attendees in-person and online. The event showcased the company's scientific leadership, global commercial strategy, and clinically proven differentiated approach to bone healing – featuring insights from a leading U.S. foot and ankle surgeon on how bone graft choice directly impacts patient outcomes and day-to-day quality of life. In addition, the Group presented the progress made in transforming its business from a functional, structural and digital perspective. New U.S. Headquarters and Production Facility Construction Underway – As part of its U.S. operational expansion strategy, Kuros has secured a location in Atlanta for a new office and manufacturing facility. The site is expected to support diversified manufacturing and enable Kuros to scale operations and engagement in line with accelerating demand for MagnetOs, with an immersive experience for surgeons, partners, and investors—highlighting the science, innovation, and clinical impact of MagnetOs in an engaging environment. Net operating costs Cost of goods sold amounted to USD 7.1 million in H1 2025 (H1 2024: USD 3.9 million) of which USD 0.9 million (H1 2024: USD 0.9 million) relate to the amortization of capitalized R&D. Net operating costs from continuing operations amounted to USD 52.8 million in H1 2025, compared to USD 32.0 million in the prior year period. Sales and marketing costs increased from USD 20.7 million in H1 2024 to USD 37.4 million in H1 2025, primarily driven by an expanded sales force and higher sales and distribution expenses, in line with the Group's continued commercial expansion. The increase also reflects the initial investments to penetrate the extremities and international markets, supporting future revenue growth and a broader market reach. Research and development costs of continuing operations increased from USD 3.6 million in H1 2024 to USD 4.3 million in H1 2025. This is primarily driven by increased R&D activities, clinical trial expenditures, and higher personnel expenses due to an increase in headcount, reflecting the Group's ongoing commitment to innovation to support long-term growth. General and administrative costs increased from USD 7.8 million in H1 2024 to USD 11.1 million in H1 2025. The increase was mainly driven by the scaling up of back-office functions and building the digital infrastructure to support business growth. Operating profit/ (loss) and group net result The operating profit from continuing operations amounted to USD 3.5 million (H1 2024: operating loss from continuing operations of USD (0.2) million). After accounting for the net finance result, income tax and the profit/loss from discontinued operations, the Group reported a net loss of USD (2.0) million in H1 2025 (H1 2024: USD (0.2) million). Financial position and other assets Cash and cash equivalents amounted to USD 18.4 million as of H1 2025 (December 31, 2024: USD 19.8 million). The decrease in cash balance compared to year-end 2024 is mainly attributable to ongoing investments in growth initiatives and working capital to support rising demand. Funds available (including trade and other receivables) for financing the operations of Kuros amounted to USD 45.3 million as of H1 2025. This is an increase of USD 7.8 million from USD 37.5 million as of December 31, 2024. As of H1 2025, total intangible assets amounted to USD 17.6 million (2024: USD 16.4 million) and goodwill amounted to USD 24.2 million (2024: USD 21.3 million). Outlook Kuros expects MagnetOs to continue its strong growth trajectory in the spine and extremity segments, gaining further market share in the U.S., Europe and the rest of the world, and launching in additional countries. The company remains sufficiently financed to support its planned organic growth path and continues to expect robust sales growth of at least 60% in 2025. Based on the solid performance in the first half of the year, Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. Key figures H1 2025 H1 2024Restated In TUSD, IFRS Revenue from product sales 63,480 35,684 Cost of goods sold (7,148) (3,896) Gross profit 56,332 31,788 Sales and marketing costs (37,394) (20,723) Research and development costs (4,305) (3,610) General and administrative costs (11,136) (7,826) Other income 6 126 Net operating costs (52,829) (32,033) Operating profit/ (loss) 3,503 (245) Net finance result (3,366) 1,857 Profit before tax 137 1,612 Income taxes (2,173) (1,466) Net (loss)/ profit from continuing operations (2,036) 146 Profit/ (loss) from discontinued operation, net of tax 23 (382) Net loss (2,013) (236) Net loss per share from continuing operations (in USD) (0.05) 0.00 Net loss per share (in USD) (0.05) (0.01) June 30, 2025 Dec 31, 2024Restated Cash and cash equivalents 18,442 19,762 Trade and other receivables 26,886 17,698 Half Year Report 2025The Kuros Biosciences Half Year Report 2025 can be downloaded via the following link on our website: Kuros Biosciences Interim Report 2025 Half Year Results 2025 – WebcastKuros will host a virtual webcast to discuss H1 2025 financial results on August 14, 2025, at 3:00pm CET. Investors can join the webcast via the following link: Investor Webcast RegistrationThe respective presentation can be downloaded via the following link:Kuros Biosciences WebCast H1 2025 Upcoming EventsOctober 16, 2025 – Trading Update Q3 2025 For further information, please contact:Kuros Biosciences AG Alexandre Müller Daniel Geiger Investor Relations Chief Financial Officer Tel +41 43 268 32 31 Tel +41 44 733 47 41 IR@ Growing bone with MagnetOsTM gives surgeons confidence where it matters most – delivering predictable fusion outcomes.2 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate (79% vs. 47%) of autograft in posterolateral fusions (PLFs).2 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.**†2,3 MagnetOs grows bone on its own thanks to NeedleGripTM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.‡§4-9 Ready-to-use, easy to mold, and reliably staying put10, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶6-9 Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions. Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. * Adjusted EBITDA excludes recurring and one-time share-based compensation and the relevant social security charges** 19 of initial 100 patients were active smokers.† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.2‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit § MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft. ¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space. Data on file. MagnetOs MIS. Stempels, et al. Spine. 2024;49(19):1323-1331. van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024. van Dijk, et al. eCM. 2021;41:756-73. van Dijk, et al. J Immunol Regen Med. 2023;19:100070. Instructions for Use (IFU) MagnetOs Granules. Instructions for Use (IFU) MagnetOs Putty. Instructions for Use (IFU) MagnetOs Easypack Putty. Instructions for Use (IFU) MagnetOs Flex Matrix. Data on file. MagnetOs Putty and MagnetOs Easypack Putty. Attachment Kuros Biosciences Press Release H1 2025 Results
Yahoo
4 hours ago
- Yahoo
Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather
By Jaspreet Kalra SINGAPORE (Reuters) -The U.S. dollar was under pressure on Thursday as traders piled into wagers that the Federal Reserve will resume cutting interest rates next month, powering Bitcoin to a record high, while a blistering rally in regional stocks took a breather. MSCI's gauge of equities in Asia excluding Japan nudged higher and lingered near its loftiest level since September 2021, taking cues from Wall Street, where the S&P 500 and Nasdaq indexes hit new closing highs for the second straight day. The MSCI All Country World Index rose to a record high for the second straight session on Wednesday. Japan's Nikkei fell after a searing six-day rally that boosted it past the 43,000 mark for the first time. Shares in Korea and Taiwan were slightly lower as well. China's blue-chip stock index and shares in Hong Kong gained. The dollar fell to a two-week low against a basket of major peers on shifting expectations of U.S. rate cuts, with comments from the U.S. Treasury Secretary also helping bolster expectations of an outsized 50 basis point cut. The Japanese yen hit a three-week high of 146.38 per dollar in early trading. [FRX/] Treasury Secretary Scott Bessent said on Wednesday that an aggressive half-point cut was possible in September after revised labour market data from last week showed that job growth had slowed sharply in May, June and July. Goldman Sachs said on Wednesday in a research note it expects the U.S. Federal Reserve to deliver three 25-basis-point interest rate cuts this year and two more in 2026. Traders are pricing in certainty of a rate cut in September with odds of a 50 bps cut rising to 7%, up from 0% a week earlier. While a tame U.S. inflation report this week boosted the case for rate cuts, some analysts have cautioned against market complacency, saying that upcoming data may alter expectations. "We're not as convinced of a 25bp FOMC rate cut in September as financial markets, let alone a 50bp rate cut," said Carol Kong, economist and currency strategist at Commonwealth Bank of Australia. "There will be another CPI and payrolls report ahead of the September meeting that can make or break the case for a rate cut," Kong said. BITCOIN, GOLD Optimism on monetary policy easing in the world's largest economy also powered cryptocurrency bitcoin to an all-time high of $124,002.49 with analysts also pointing to recent financial sector reforms as a tailwind for the asset class. Bitcoin has risen 32% so far in 2025, and the second largest cryptocurrency, Ethereum, has climbed 41% and is hovering just shy of its all-time high hit in November 2021. In commodity markets, gold prices rose 0.5% to $3,371 and crude oil prices edged up after hitting a two-month low on Wednesday as investors kept their focus on the summit between U.S. President Donald Trump and Russian leader Vladimir Putin on Friday. [O/R] [GOL/] Trump on Wednesday threatened "severe consequences" if Putin did not agree to peace in Ukraine but also said that a meeting between them could swiftly be followed by a second one that would include Ukrainian President Volodymyr Zelenskiy. In the past, Trump has said both sides will have to swap land to end fighting that has cost tens of thousands of lives and displaced millions. "While lack of progress towards a ceasefire may lead to renewed threats of secondary oil tariffs/sanctions, we see limited risk of large disruptions in Russia supply," analysts at Goldman Sachs wrote in a note. Large volumes of Russian exports, the possibility of deepening price discounts to maintain demand, and the likely eagerness of key buyers India, and especially China, to continue energy cooperation with Russia are expected to avert major disruptions, they said. Trump signed an executive order last week levying an additional 25% tariff on India's exports to the U.S., saying that the country directly or indirectly imported Russian oil. He has also hinted at similar tariffs on China.
